Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Tocilizumab, an anti-interleukin-6 (IL-6) agent, is indicated as a treatment for several autoimmune or inflammatory diseases, including rheumatoid arthritis and juvenile idiopathic arthritis (JIA). IL-6 plays roles in both immune system dysregulation and inflammation, and thus efforts to extend the...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Ju-Yang, Kim, Moon-Young, Suh, Chang-Hee, Kim, Hyoun-Ah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295005/
https://www.ncbi.nlm.nih.gov/pubmed/30547812
http://dx.doi.org/10.1186/s12969-018-0296-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295005/
https://www.ncbi.nlm.nih.gov/pubmed/30547812
http://dx.doi.org/10.1186/s12969-018-0296-z

Ejemplares similares